News
Applying PGx-guided drug therapy in decision making for diabetes and elderly patients
The use of clopidogrel and PPIs either alone or in combination is quite widespread, in particular among the elderly and persons with diabetes. This further supports the emerging need of accessing and accounting for not only DDI (drug-drug-interactions) but also for applying PGx-guided drug therapy in clinical decision making for [...]
Personalized Medicine for patients with depression and/or anxiety
The literature on pharmacogenomics as a tool to support antidepressant precision is burgeoning. In this prospective, single-blind randomized controlled design, the impact of pharmacogenomics guided versus standard antidepressant was evaluated. Participants were 213 outpatients diagnosed with major depressive disorder and/ or generalized anxiety disorder, randomized to receive pharmacogenomics guided (n [...]
A large fraction of elderly Danes are exposed to drugs with “actionable guidelines”
A Danish register study shows that 49 drugs have "actionable guidelines" related to CYP2C6 and CYP2C19 corresponding 14.5% of the total sales in DDD. Pantoprazole, lansoprazole, omeprazole, clopidogrel and metoprolol constituted fifty-eight percent of the consumption in DDD of drugs having "actionable guidelines". The consumption of antidepressant drugs, opioides, and [...]
FDA: pharmacogenomics can play an important role in identifying responders to medication
Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe: Drug exposure and clinical response variability Risk for adverse events Genotype-specific dosing Mechanisms of drug action Polymorphic drug [...]
Approx. half the population over 65 years in Germany can have an elevated risk
Around 9 million of the 17 million individuals aged ≥65 years in Germany potentially have an elevated risk for adverse drug reactions and 4.6 million potentially have a highly elevated risk. Analyses were based on the first 5,000 participants of the Rhineland Study (mean age 55 years; 57% women). [...]
Plavix manufacturers to pay $834 million in penalty
Bristol-Myers Squibb Co and Sanofi, the manufacturers of Plavix (clopidogrel) have been ordered to pay over $834 million to the state of Hawaii after failing to warn about the drug’s potential health risks to patients with combinations of CYP2C19 variants which result in a CYP2C19 poor metabolizer status. Clopidogrel is [...]